# A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

> **NCT06234605** · PHASE1 · RECRUITING · sponsor: **HiberCell, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** HC-7366
- **DRUG:** Belzutifan

## Key facts

- **NCT ID:** NCT06234605
- **Lead sponsor:** HiberCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-29
- **Primary completion:** 2026-11
- **Final completion:** 2027-11
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06234605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06234605, "A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06234605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*